COVID-19 Resource Community

Our institution is actively considering the use of the monoclonal antibodies that have received emergency use authorization from the FDA (casirivimab+iimdevimab and/or bamlanivimab). While we have chosen not to plan use for the general population, we'd like to consider use for high-risk populations. Do any other institutions have such policies in place?

Thanks,
Brandon Hayes-Lattin

------------------------------
Brandon Hayes-Lattin MD
Oregon Health & Science Univ
Portland OR
(503) 494-8534
------------------------------

Yes. We set up a pharmacy and therapeutics review specific for COVID-19 related therapies. We review data and develop access/use criteria. We adopted criteria for use in immunocompromised including solid organ and stem cell transplant.
Dianna Howard

Sent from my iPad


Original Message:
Sent: 12/6/2020 9:36:00 AM
From: Brandon Hayes-Lattin
Subject: Monoclonal antibodies under EUA

Our institution is actively considering the use of the monoclonal antibodies that have received emergency use authorization from the FDA (casirivimab+iimdevimab and/or bamlanivimab). While we have chosen not to plan use for the general population, we'd like to consider use for high-risk populations. Do any other institutions have such policies in place?

Thanks,
Brandon Hayes-Lattin

------------------------------
Brandon Hayes-Lattin MD
Oregon Health & Science Univ
Portland OR
(503) 494-8534
------------------------------

Would you be willing to share that work and criteria? We are struggling a bit to convince our center's leadership to pursue this. Thanks!
BHL
hayeslat@ohsu.edu

------------------------------
Brandon Hayes-Lattin MD
Oregon Health & Science Univ
Portland OR
(503) 494-8534
------------------------------

Original Message:
Sent: 12-07-2020 06:56
From: Dianna Howard
Subject: Monoclonal antibodies under EUA

Yes. We set up a pharmacy and therapeutics review specific for COVID-19 related therapies. We review data and develop access/use criteria. We adopted criteria for use in immunocompromised including solid organ and stem cell transplant.
Dianna Howard

Sent from my iPad


Original Message:
Sent: 12/6/2020 9:36:00 AM
From: Brandon Hayes-Lattin
Subject: Monoclonal antibodies under EUA

Our institution is actively considering the use of the monoclonal antibodies that have received emergency use authorization from the FDA (casirivimab+iimdevimab and/or bamlanivimab). While we have chosen not to plan use for the general population, we'd like to consider use for high-risk populations. Do any other institutions have such policies in place?

Thanks,
Brandon Hayes-Lattin

------------------------------
Brandon Hayes-Lattin MD
Oregon Health & Science Univ
Portland OR
(503) 494-8534
------------------------------

Hi Brandon,  email me at dhoward@wakehealth.edu and I will share what we have.
Dianna Howard
 ​

------------------------------
Dianna Howard MD
Director, SCTCT Program
Wake Forest Comprehensive Cancer Center
Clemmons NC
336-716-7972
------------------------------

Original Message:
Sent: 12-09-2020 19:21
From: Brandon Hayes-Lattin
Subject: Monoclonal antibodies under EUA

Would you be willing to share that work and criteria? We are struggling a bit to convince our center's leadership to pursue this. Thanks!
BHL
hayeslat@ohsu.edu

------------------------------
Brandon Hayes-Lattin MD
Oregon Health & Science Univ
Portland OR
(503) 494-8534

Original Message:
Sent: 12-07-2020 06:56
From: Dianna Howard
Subject: Monoclonal antibodies under EUA

Yes. We set up a pharmacy and therapeutics review specific for COVID-19 related therapies. We review data and develop access/use criteria. We adopted criteria for use in immunocompromised including solid organ and stem cell transplant.
Dianna Howard

Sent from my iPad


Original Message:
Sent: 12/6/2020 9:36:00 AM
From: Brandon Hayes-Lattin
Subject: Monoclonal antibodies under EUA

Our institution is actively considering the use of the monoclonal antibodies that have received emergency use authorization from the FDA (casirivimab+iimdevimab and/or bamlanivimab). While we have chosen not to plan use for the general population, we'd like to consider use for high-risk populations. Do any other institutions have such policies in place?

Thanks,
Brandon Hayes-Lattin

------------------------------
Brandon Hayes-Lattin MD
Oregon Health & Science Univ
Portland OR
(503) 494-8534
------------------------------